“Did you say 40 months?”
DESTINY-Breast09 delivered one of the most practice-changing datasets in HER2-positive metastatic breast cancer:
• ~40-month median PFS
• ~15% complete responses
• Benefit across subgroups
• Strong CNS signal
Is this the moment CLEOPATRA is finally replaced?
DESTINY-Breast09: 40-Month PFS — A New First-Line Reality for HER2+ Disease?
You may also like
Recommended Videos
